Misonix, Inc.  

(Public, NASDAQ:MSON)   Watch this stock  
Find more results for MSON
5.75
-0.02 (-0.35%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.50 - 5.90
52 week 1.92 - 9.13
Open 5.68
Vol / Avg. 5,600.00/13,924.00
Mkt cap 40.73M
P/E     -
Div/yield     -
EPS -0.09
Shares 7.08M
Beta 0.92
Inst. own 13%
May 9, 2013
Q3 2013 Misonix Earnings Conference Call - Webcast
May 6, 2013
Q3 2013 Misonix Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -18.92% -3.88%
Operating margin -33.31% -9.50%
EBITD margin - -4.95%
Return on average assets -15.00% -3.32%
Return on average equity -17.02% -4.00%
Employees 69 -
Carbon Disclosure Rating - -

Address

1938 New Highway
FARMINGDALE, NY 11735
United States - Map
+1-631-6949555 (Phone)
+1-631-6949412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

MISONIX, INC. (Misonix) designs, manufactures, develops and markets minimally invasive ultrasonic surgical device products. These products include the BoneScalpel cutting systemwhich is used among other things for surgical procedures of the spine and on maxillofacial procedures, the SonaStar Surgical Aspirator which is used to emulsify and remove soft and hard tumors, the SonicOne Wound Cleansing and Debridement System that offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells, and the AutoSonix ultrasound cutting and coagulating system, which is distributed and marketed for Misonix through an agreement with Covidien Ltd. Misonix also markets its Lysonix ultrasound assisted liposuction device through Mentor Corporation, a subsidiary of Johnson & Johnson . On October 19, 2011, it sold its Laboratory and Forensic Safety Products business to Mystaire, Inc.

Officers and directors

Michael A. McManus Jr. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Richard Zaremba Chief Financial Officer, Senior Vice President, Secretary, Treasurer
Age: 57
Bio & Compensation  - Reuters
Frank Napoli Vice President - Operations
Age: 55
Bio & Compensation  - Reuters
Robert Scott Ludecker Global Vice President - Sales and Marketing
Age: 45
Bio & Compensation  - Reuters
Ronald Manna Vice President - New Product Development and Regulatory Affairs
Age: 58
Bio & Compensation  - Reuters
Daniel Voic Vice President - Research & Development and Engineering
Age: 50
Bio & Compensation  - Reuters
Stavros Vizirgianakis Director
Bio & Compensation  - Reuters
Howard Alliger Independent Director
Age: 85
Bio & Compensation  - Reuters
John W. Gildea Independent Director
Age: 69
Bio & Compensation  - Reuters
Charles Miner III Independent Director
Age: 61
Bio & Compensation  - Reuters